The Mainstay of Treatment will be Changed: Cytoreductive Nephrectomy Would Not be Required in Intermediate and Poor Risk Patients with Metastatic Renal Cell Carcinoma Cancer

Abstract

To date, cytoreductive nephrectomy before systemic therapy is generally recommended in patients with a potentially surgically resectable primary renal cell carcinoma (RCC) and multiple metastases. Targeted therapy with tyrosine kinase inhibitors is widely used in the firstline treatment of metastatic renal cell carcinoma. The objective of CARMENA study was to determine whether cytoreductive surgery before the initiation of the targeted therapy in patients with metastatic renal cell carcinoma (mRCC) is required.